Actively Recruiting
Phase I Study to Assess Safety, Tolerability, and Antitumor Effects of JSKN022 in Adults with Advanced Malignant Solid Tumors
Led by Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Updated on 2025-12-23
225
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor effects of the drug JSKN022 in patients with advanced malignant solid tumors. This Phase I, open-label, multi-center trial focuses on patients with advanced unresectable or metastatic epithelial-derived malignant solid tumors who have either failed standard treatments, cannot tolerate them, or lack access to standard treatments. The main goal is to find the maximum tolerated dose and recommended Phase II dose of JSKN022. Participants will receive JSKN022 intravenously at selected dose levels following the study protocol. The study includes various dose escalation cohorts and dose optimization cohorts targeting different tumor types. The treatment period and dose adjustments will be monitored closely to evaluate safety and antitumor activity. During the trial, participants will undergo regular assessments including imaging to measure tumor lesions, laboratory tests to monitor organ function, and evaluations for adverse events. Researchers will track drug levels and immune responses to JSKN022 over up to 24 months. The primary outcomes include treatment-related side effects, dose-limiting toxicities, and determination of the optimal dose. Secondary outcomes assess tumor response, disease control, survival rates, and detailed pharmacokinetic parameters. Participants will be followed from initial dosing until disease progression, new treatment, withdrawal, death, or study end.
CONDITIONS
Brief Title
JSKN022 in Subjects With Advanced Malignant Solid Tumors
Research Team
R
Ruihua Xu, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here